Nflection Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Chestnut Hill, MA, dedicated to revolutionizing the treatment of rare dermatological diseases. Their primary focus lies in the discovery and development of targeted topical therapies for disorders driven by abnormal activation of the RAS pathway, such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks.
With a commitment to addressing RAS-mediated conditions through innovative approaches, Nflection Therapeutics is developing first-in-class MEK mitogen-activated protein kinase kinase inhibitors for topical treatment, aiming to provide effective solutions for patients suffering from these challenging conditions.
Generated from the website